MedTrace Logo

Unifying Advanced Treatment With Advanced Imaging

NCT03404076 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2022-04-07

No results posted yet for this study

Summary

The study investigates response assessment of gastrointestinal stromal tumors using Dual Energy CT (DECT) in patients undergoing targeted therapy with a TKI Inhibitor.

Conditions

  • Gastrointestinal Stromal Tumor (GIST)

Interventions

DIAGNOSTIC_TEST

Dual Energy CT

Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment

Sponsors & Collaborators

  • Institute of Clinical Radiology and Nuclear Medicine Mannheim

    collaborator UNKNOWN

  • Siemens Healthcare Diagnostics Inc

    collaborator INDUSTRY

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Peter Hohenberger, Prof., MD · Clinical for Surgery, Section SCOTCH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-01
Primary Completion
2020-10-31
Completion
2020-12-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03404076 on ClinicalTrials.gov